Literature DB >> 178462

Receptor binding of angiotensin II and antagonists. Correlation with aldosterone production by isolated canine adrenal glomerulosa cells.

J Douglas, S Saltman, P Fredlund, T Kondo, K J Catt.   

Abstract

The binding properties of the angiotensin II receptors of the adrenal cortex have been studied in isolated cells prepared by collagenase dispersion of the zona glomerulosa of the canine adrenal gland. Such cell preparations are responsive to physiological concentrations of angiotensin II, and permit correlation of binding of angiotensin II and its analogues with aldosterone production in vitro. Uptake of 125I-angiotensin II (5 X 10(-11) M) by glomerulosa cells at 37 degrees C reached a steady state at 45 minutes, with a subsequent plateau for at least 60 minutes. Angiotensin II binding was also dependent upon the hormone and cell concentrations employed during uptake studies. Bound angiotensin II was rapidly dissociated from canine adrenal cells after addition of the unlabeled octapeptide. High affinity sites with equilibrium association constant (Ka) of 3.3 X 10(9) M-1 comprised 25-33% of the receptor population and the remainder of the sites were of lower affinity, 2.5 X 10(8)M-1. Binding of angiotensin II analogues and antagonists was found to be consistent with their biological activities. The analogue most extensively evaluated was [Sar-1]angiotensin II, which exhibited enhanced binding activity when compared to angiotensin II, and had a higher equilibrium association constant by kinetic analysis and direct binding studies. Direct binding of labeled angiotensin II to the adrenal glomerulosa receptor has been correlated with a progressive response in aldosterone production. The steroidogenic response to angiotensin II was maximal when 25% of the receptor population was occupied; this fraction corresponds to the proportion of high affinity receptor sites measured by binding analysis. In addition, inhibition of angiotensin II binding to receptor sites by the competitive antagonist [Sar-1, Ala-8]angiotensin II has been correlated with inhibition of aldosterone production. These findings serve to demonstrate the biological significance of the angiotensin II binding sites of the adrenal cortex, and confirm their role as receptors which mediate the steroidogenic responses to angiotensin II.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 178462     DOI: 10.1161/01.res.38.6.108

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  7 in total

1.  Control of aldosterone secretion during sodium restriction: adrenal receptor regulation and increased adrenal sensitivity to angiotensin II.

Authors:  G Aguilera; R L Hauger; K J Catt
Journal:  Proc Natl Acad Sci U S A       Date:  1978-02       Impact factor: 11.205

2.  Angiotensin alters 45Ca2+ fluxes in bovine adrenal glomerulosa cells.

Authors:  M E Elliott; T L Goodfriend
Journal:  Proc Natl Acad Sci U S A       Date:  1981-05       Impact factor: 11.205

3.  The effect of chronic captopril therapy on platelet angiotensin II receptor density and vascular responsiveness to angiotensin II infusion.

Authors:  G B Kondowe; J G Kelly; S Copeland; G D Johnston
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

4.  Local generation of angiotensin II as a mechanism of regulation of peripheral vascular tone in the rat.

Authors:  J A Oliver; R R Sciacca
Journal:  J Clin Invest       Date:  1984-10       Impact factor: 14.808

5.  Regulation of angiotensin II receptors in the rat adrenal cortex by dietary electrolytes.

Authors:  J Douglas; K J Catt
Journal:  J Clin Invest       Date:  1976-10       Impact factor: 14.808

6.  Isolation of an angiotensin II-binding protein from liver.

Authors:  I Sen; H G Bull; R L Soffer
Journal:  Proc Natl Acad Sci U S A       Date:  1984-03       Impact factor: 11.205

7.  Development of affinity resins for isolation of angiotensin receptors.

Authors:  F M Finn; K Hofmann
Journal:  Yale J Biol Med       Date:  1985 Nov-Dec
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.